
Bioporto A/S
CSE:BIOPOR

Gross Margin
Bioporto A/S
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
DK |
![]() |
Bioporto A/S
CSE:BIOPOR
|
603.2m DKK |
65%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
334.3B USD |
71%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
160.4B USD |
64%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
139.1B USD |
78%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.1B USD |
86%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
117B AUD |
52%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
59.2B USD |
87%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
43.3B USD |
86%
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Bioporto A/S's most recent financial statements, the company has Gross Margin of 64.6%.